Form 6-K Aeterna Zentaris Inc. For: Jun 21

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2022

 

Commission File Number: 001-38064

 

Aeterna Zentaris Inc.

(Translation of registrant’s name into English)

 

c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

 

 

 

Exhibits 99.1 included with this report on Form 6-K are hereby incorporated by reference into the Registrant’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561 and No. 333-200834), Forms F-3 (No.333-232935 and No. 333-254680) and Forms F-1 (No.333-239264, No. 333-248561 and No. 333-239019)and shall be deemed to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

 

DOCUMENTS INDEX

 

Exhibit		Description
99.1		Report of Voting Results Submitted Pursuant to Section 11.3 of National Instrument 51-102

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

		AETERNA ZENTARIS INC.
Date: June 21, 2022		By:	/s/ Klaus Paulini
			Klaus Paulini
			President and Chief Executive Officer

 

 

Exhibit 99.1

 

AETERNA ZENTARIS INC.

 

Report of Voting Results

Submitted Pursuant to

Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations

 

June 21, 2022

 

In accordance with Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations, this report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of Aeterna Zentaris Inc. (the “Company”) held on June 21, 2022 via live audio webcast. Each of the matters is described in greater detail in the Company’s management information circular dated May 16, 2022 (the “Circular”).

 

(a)

The five nominees set forth in the Circular were elected as directors of the Company to hold office until the close of the next annual meeting of the Company’s shareholders or until their successors are duly elected or appointed. The following are the voting results on this matter:

 

		FOR				% FOR				WITHHELD				%WITHHELD
Peter Edwards			10,264,600				75.75	%			3,285,758				24.25	%
Carolyn Egbert			9,712,946				71.68	%			3,837,412				28.32	%
Gilles Gagnon			9,719,864				71.73	%			3,830,494				28.27	%
Klaus Paulini			10,178,648				75.12	%			3,371,711				24.88	%
Dennis Turpin			10,375,735				76.57	%			3,174,623				23.43	%

 

(b)

Ernst & Young LLP was appointed as the Company’s auditors and the directors were authorized to fix the remuneration to be paid to the auditors. The following are the voting results on this matter:

 

		FOR				% FOR				WITHHELD				% WITHHELD
Appointment of Auditors			28,148,915				85.49	%			4,777,318				14.51	%

 

(c)

The Company’s Amended and Restated Shareholder Rights plan was reconfirmed and approved.

 

		FOR				% FOR				WITHHELD				% WITHHELD
Shareholder Rights Plan			7,464,681				55.09	%			6,085,677				44.91	%

 

Dated this 21^st day of June, 2022.

 

	AETERNA ZENTARIS INC.
	By:	(signed) Giuliano La Fratta
	Name:	Giuliano La Fratta
	Title:	Chief Financial Officer

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Orion Group Interim Report January–March 2024
• Šiaulių Bankas invitation to Q1 2024 Financial Results webinar
• REVIVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reviva Pharmaceuticals Holdings, Inc. on Behalf of Reviva Stockholders and Encourages Investors to Contact the Firm